8.34  0.97 (13.16%)		04-30 16:00
Open: 7.5 High: 8.48 Volume: 756,355		Pre. Close: 7.37 Low: 7.5 Market Cap: 734(M)

Short term
Mid term
Targets	6-month :	9.9	1-year :	11.56
Resists	First :	8.47	Second :	9.9
Pivot price	7.84
Supports	First :	7.16	Second :	6.35
MAs	MA(5) :	7.8	MA(20) :	7.65
	MA(100) :	6.78	MA(250) :	4.78
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	40.8	D(3) :	43.2
RSI	RSI(14): 61.9
52-week	High :	8.6	Low :	2.54

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DRTS ] has closed below upper band by 9.4%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.49 - 8.52	8.52 - 8.56
Low:	7.42 - 7.45	7.45 - 7.49
Close:	8.27 - 8.33	8.33 - 8.4

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Mon, 27 Apr 2026
Alpha Tau Medical (NASDAQ: DRTS) files $300M shelf; $100M ATM pact - Stock Titan

Mon, 27 Apr 2026
Alpha Tau to Present Pooled Pancreatic Cancer Alpha DaRT Data at 2026 ASCO Meeting - TipRanks

Mon, 27 Apr 2026
A 58-patient pancreatic cancer study puts Alpha Tau at ASCO - Stock Titan

Mon, 27 Apr 2026
Alpha Tau Announces Presentation of Pancreatic Cancer Data - GlobeNewswire

Mon, 27 Apr 2026
Alpha Tau (Nasdaq: DRTS) ASCO abstract pools 58 pancreatic cancer patients - Stock Titan

Mon, 27 Apr 2026
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	88 (M)
Shares Float	45 (M)
Held by Insiders	32 (%)
Held by Institutions	2.9 (%)
Shares Short	771 (K)
Shares Short P.Month	595 (K)

EPS	-0.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.87
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-27.6 %
Return on Equity (ttm)	-61 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.47
Qtrly Earnings Growth	0 %
Operating Cash Flow	-27 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-15.74
PEG Ratio	0
Price to Book value	9.47
Price to Sales	0
Price to Cash Flow	-27.52

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.